Regional Guides

Introduction: Why Regional Information Matters

Psilocybin — the active compound in "magic mushrooms" — occupies one of the most complex and rapidly evolving legal landscapes of any psychoactive substance in the world. Whether you are seeking to understand your rights, access therapeutic services, participate in a clinical trial, reduce harms, or simply understand what is happening globally, the answer depends almost entirely on where you are.

In Oregon, an adult can legally book a session at a licensed psilocybin service centre with no medical diagnosis required. In the UK, the same substance carries a potential life sentence for supply. In the Netherlands, you can walk into a shop in Amsterdam and buy psilocybin truffles legally. In Jamaica, there are no specific laws against psilocybin at all. In Canada, a terminal cancer patient can receive psilocybin therapy through a Health Canada exemption, while general possession remains a criminal offence.

This diversity of legal contexts means that what is true in one jurisdiction tells you almost nothing about what is true in another. These regional guides are designed to help you navigate that complexity with accurate, nuanced, and harm-reduction oriented information.

Global Legal Landscape: An Overview

Before diving into specific regions, it is helpful to understand the broad categories of legal status that countries have adopted. Psilocybin's legal context typically falls into one of these frameworks:

Fully Illegal (Most of the World)

The majority of countries have psilocybin listed as a controlled substance with no legal pathway for personal use. This includes the United States at the federal level (Schedule I), the United Kingdom (Class A), most of the European Union (though enforcement and exact scheduling varies by member state), Australia, Canada (with exceptions), Japan, and most of Asia, Africa, and Latin America. In many of these jurisdictions, enforcement against personal possession is rare, but the legal risk is real.

Decriminalised Personal Use

A growing number of jurisdictions have removed criminal penalties for personal possession of small amounts while leaving supply and production illegal. This includes Portugal (all drugs since 2001), the Netherlands (in practice, though not technically scheduled separately from mushrooms), Czech Republic, and specific US cities including Denver, Oakland, Santa Cruz, Seattle, and Washington DC. British Columbia, Canada received a temporary personal possession decriminalisation in 2023 (with subsequent modifications). Decriminalisation does not create a legal supply — you may not be arrested for small amounts, but obtaining the substance still typically involves an illegal transaction.

Regulated Therapeutic or Commercial Access

The newest and most developed category of reform creates licensed frameworks for access with professional oversight. This includes Oregon's Measure 109 (service centres, 2023), Colorado's Proposition 122 (healing centres, 2024), and Australia's rescheduling of psilocybin as a Schedule 8 controlled medicine for treatment-resistant depression and PTSD under psychiatrist supervision (effective February 2023). These frameworks balance access with safety requirements but come with costs and clinical gatekeeping.

Effectively Legal (No Specific Scheduling)

A small number of jurisdictions have never scheduled psilocybin specifically and thus have no law making it illegal. Jamaica is the clearest example — psilocybin mushrooms are not scheduled under Jamaican law, making retreat operations and personal use effectively legal. The British Virgin Islands and a few other territories are in similar positions. These are exceptions rather than the rule globally.

Legal Within Cultural or Ceremonial Frameworks

Some jurisdictions recognise psilocybin use within specific ceremonial contexts. The US federal exemption for peyote (a different psychedelic) in Native American Church ceremonies demonstrates one model. Mexico recognises Mazatec ceremonial mushroom use in the Oaxaca region, though enforcement of general mushroom laws elsewhere in Mexico is inconsistent. Several Latin American countries have similar traditional-use contexts.

Region-by-Region Summary Table

Region / Country	Legal Status Summary	Key Development
United States (federal)	Schedule I — fully illegal	Oregon and Colorado have state regulated access; 30+ cities have decriminalised
Oregon (US state)	Licensed service centres legal	Measure 109 (2020) — services operational since 2023
Colorado (US state)	Personal possession decriminalised; healing centres licensed	Prop 122 (2022) — decrim immediate; centres from 2024
Canada	Schedule III — illegal; SAP/Section 56 medical exceptions	BC personal decrim (2023, modified 2024); growing research ecosystem
Jamaica	Not scheduled — effectively legal	Major retreat industry operating legally
Netherlands	Truffles legal; mushrooms illegal	Active truffle commerce in smart shops; retreat industry
Portugal	Personal possession decriminalised (all drugs)	2001 decrim; supply still illegal; no specific therapeutic framework
Czech Republic	Personal possession decriminalised	2010 decrim for small amounts; supply still illegal
Austria	Controlled but possession treated as health matter	Similar to Portugal model in practice; supply illegal
United Kingdom	Class A — most serious UK category	World-leading research at Imperial; COMPASS Pathways; no clinical access pathway
Australia	Schedule 8 for approved clinical use (TGA, Feb 2023)	Psychiatrists may prescribe for TRD and PTSD — first such framework in Oceania
New Zealand	Class A equivalent — fully illegal	Active research and advocacy; no clinical access pathway yet
Brazil	Psilocybin not explicitly scheduled	Complex legal situation; mushrooms in grey area; ayahuasca ceremonies legally protected
Mexico	Illegal nationally; traditional use in Oaxaca tolerated	Mazatec ceremonial use has cultural and some legal protection in practice
Germany	Controlled — illegal for personal use	Active research; recent cannabis reform may inform psychedelic policy
Switzerland	Controlled; exceptional use licences possible	LSD/psilocybin therapy research active; some compassionate-use precedents
Israel	Controlled; expanding compassionate use	MAPS MDMA trials; psilocybin research at Hebrew University; compassionate access expanding
Japan	Strictly controlled; severe penalties	Very limited research; no reform pathway evident; high enforcement
Spain	Personal use decriminalised; social clubs tolerated	Similar to cannabis "social club" model; possession in private not prosecuted

Americas

United States

The US presents the most complex picture of any country, with federal Schedule I status coexisting with a patchwork of state and city-level reforms. Federal law classifies psilocybin as Schedule I — meaning no accepted medical use and high abuse potential — making possession, distribution, and manufacture federal crimes. However, under the Tenth Amendment and in practice, the federal government has largely deferred to state law in jurisdictions that have reformed their approach.

The two landmark statewide reforms are Oregon (Measure 109, 2020 — licensed service centres) and Colorado (Proposition 122, 2022 — personal decriminalisation and healing centres). Both are fully operational as of 2025 and represent the most developed regulatory frameworks for psilocybin access anywhere in the world.

At the city level, over 30 municipalities have passed resolutions deprioritising or decriminalising psilocybin enforcement, including Denver (2019 — the first in the US), Oakland, Santa Cruz, Ann Arbor, Detroit, Seattle, and Washington DC. These are not legalisation measures — supply remains illegal — but they signal enforcement priorities and provide some legal protection for personal possession.

Several additional states have active reform campaigns, including California, New York, Massachusetts, and Minnesota. The landscape continues to change rapidly.

Detailed guides: Oregon Psilocybin Services Guide | Colorado Natural Medicine Health Act Guide | North America Overview

Canada

Canada occupies a middle position — psilocybin remains a Schedule III controlled substance under federal law, but Health Canada has created meaningful legal access pathways through Section 56 exemptions (individual case-by-case exemptions) and the Special Access Programme (SAP), which since 2022 explicitly covers restricted drugs including psilocybin for patients with serious or life-threatening conditions.

British Columbia's 2023 personal possession exemption (subsequently modified) represents the first provincial-level decriminalisation in Canadian history. Canada is also home to a world-class psychedelic research ecosystem centred at CAMH (Toronto), UBC (Vancouver), and McGill (Montreal).

Detailed guide: Canada Psilocybin Guide

Jamaica

Jamaica is arguably the world's most permissive jurisdiction for psilocybin. The substance is not listed in Jamaica's Dangerous Drugs Act, meaning there is no specific law against possession, production, or supply. This has enabled a legal retreat industry serving primarily North American and European visitors. Operators offer guided psilocybin sessions, typically within ceremonial or therapeutic frameworks. Quality of facilitation varies significantly between retreat centres — thorough research before booking is essential.

Detailed guide: Jamaica Psilocybin Guide

Brazil and Latin America

Brazil presents a legally interesting situation — psilocybin mushrooms were removed from Brazil's Schedule I list in 2010, making them technically unregulated (neither legal nor illegal in the traditional sense). Ayahuasca — a DMT-containing brew with deep roots in Brazilian culture — is fully legal for ceremonial use. Mexico has important traditional use contexts, particularly the Mazatec mushroom ceremonies of Oaxaca. Peru and Ecuador have long traditions of plant medicine ceremony. Latin America as a whole is a patchwork of formal laws and informal tolerances.

Detailed guide: South America Psilocybin Guide

Europe

United Kingdom

The UK's Class A classification of psilocybin is among the most restrictive in the developed world — placing psilocybin alongside heroin and crack cocaine in terms of legal penalties. Yet the UK hosts some of the world's most influential psilocybin research programmes, including Imperial College London's Centre for Psychedelic Research and COMPASS Pathways (a UK-listed clinical-stage company). The gap between the scientific evidence and legal status has generated growing policy debate, with the ACMD and Drug Science both active on the issue.

For UK residents, the only legal therapeutic access is through clinical trials. Some residents travel to the Netherlands or Jamaica for experiences. Bringing any product back to the UK is a serious criminal offence.

Detailed guide: United Kingdom Psilocybin Guide

Netherlands

The Netherlands occupies a unique position: psilocybin mushrooms (paddos) are illegal, but psilocybin truffles — the underground sclerotia of the same species — remain legal for sale in smart shops. This legal quirk has given rise to a substantial truffle commerce industry in Amsterdam and other cities, and an expanding retreat sector offering guided experiences with professional facilitation. The Netherlands is also a growing hub for psychedelic-assisted therapy training and research.

Detailed guide: Netherlands Psilocybin Guide

Portugal

Portugal's 2001 decriminalisation of personal possession of all drugs — including psilocybin — for personal use is one of the most studied drug policy experiments in the world. Possession of small amounts is treated as a health matter rather than a criminal one, with referral to Dissuasion Commissions rather than prosecution. Supply remains illegal. Portugal does not have a therapeutic access framework for psilocybin, but its harm-reduction infrastructure is extensive.

Germany and Continental Europe

Germany's 2024 cannabis legalisation has intensified interest in broader drug policy reform, including psychedelics. While psilocybin remains controlled across most of Europe, active research programmes exist in Germany, Switzerland, and Czechia. Switzerland has historical significance as the origin of LSD research and has some precedents for exceptional-use licences. The Czech Republic's broad personal possession decriminalisation offers some practical tolerance for personal use.

Detailed guide: Europe Psilocybin Guide

Oceania

Australia

Australia made history in February 2023 when the Therapeutic Goods Administration (TGA) rescheduled psilocybin from Schedule 9 (prohibited) to Schedule 8 (controlled medicine) for specific therapeutic uses. As of July 2023, authorised psychiatrists can prescribe psilocybin for treatment-resistant depression and MDMA-assisted therapy for PTSD. This makes Australia the first country to formally legalise therapeutic psilocybin access outside of clinical trials. Access requires a psychiatrist, specific qualifying diagnoses, and prior treatment failures — it is not general access — but it represents a significant global milestone.

Detailed guide: Oceania Psilocybin Guide

New Zealand

New Zealand maintains a strict drug classification for psilocybin with no current therapeutic pathway, though research interest and advocacy are active. New Zealand has a progressive harm-reduction infrastructure in other areas (its drug checking legislation is world-leading) that may eventually support psychedelic reform.

Asia

Asia presents the most uniformly restrictive legal landscape for psilocybin globally. Japan, South Korea, China, Indonesia, Thailand, and most other Asian nations maintain strict controls with significant penalties — in some countries, including Indonesia and Singapore, drug offences can carry capital punishment. There are traditional use contexts in some regions (certain Indigenous communities in Southeast Asia, for example), but these are not formally protected.

India's legal status is complex — psilocybin is not clearly scheduled under the Narcotic Drugs and Psychotropic Substances Act, creating legal ambiguity, though this is not a reliable protection.

Detailed guide: Asia Psilocybin Guide

Africa

Most African nations have psilocybin controlled under national legislation. South Africa is a notable exception — psilocybin mushroom spores are not scheduled, and the legal status of the dried mushroom itself is uncertain enough that possession is rarely prosecuted, particularly in the Western Cape. Traditional use of various psychoactive plants in ceremonial contexts exists across many African cultures, with varying formal legal status.

Detailed guide: Africa Psilocybin Guide

Key Global Developments to Watch

The psilocybin legal landscape is changing faster than at any point in the post-1971 (UN Convention on Psychotropic Substances) era. Key developments likely to shape the next few years:

• FDA review of psilocybin — COMPASS Pathways and other companies have Phase 3 trials underway in the US. If data is positive, an FDA New Drug Application could follow. FDA approval would create enormous pressure on states and insurers to follow suit.
• US state reform wave — California, New York, and several other large states have active ballot or legislative campaigns. A California measure would likely influence national and international policy significantly.
• EU harmonisation pressures — as individual EU member states develop different approaches (Netherlands, Portugal, Germany), pressure for EU-level guidance on psychedelic research and therapeutic access is growing.
• UK rescheduling debate — calls to move psilocybin from Schedule 1 (no therapeutic use) to Schedule 2 (allows therapeutic use under licence) continue to grow, even without movement on the Class A criminal classification.
• Australia's real-world data — Australia's therapeutic access programme is generating the first real-world clinical data on psilocybin in a regulated medical context outside of trials. This data will influence global reform debates.
• Indigenous rights frameworks — internationally, growing recognition of Indigenous rights to plant medicines used in traditional ceremonies is creating legal arguments for exemptions across multiple jurisdictions.

How Harm Reduction Applies Regardless of Legality

Whatever the legal context in your jurisdiction, the evidence-based harm-reduction principles for psilocybin are consistent. Psilobase's Safety & Harm Reduction section covers these in detail. Key points that apply everywhere:

• Know your contraindications — personal or family history of psychosis, schizophrenia, or bipolar I disorder represents a contraindication regardless of legal context. Lithium and MAOIs should not be combined with psilocybin under any circumstances.
• Set and setting — your mindset and physical environment are the most controllable determinants of experience quality and safety. Intentional preparation matters regardless of whether you are in a licensed Oregon service centre or your own home.
• Dosing conservatively — psilocybin effects are highly variable by individual, mushroom strain, and circumstances. Erring on the side of a lower dose is always the safer choice, particularly if inexperienced or in an uncontrolled environment.
• Sober sitter — having a trusted, calm, sober companion present for any significant dose is one of the most important safety factors. This applies in both licensed and informal contexts.
• Integration matters — how you process and apply the insights and experiences that arise from psilocybin use may matter more than the experience itself. Seek integration support from a qualified therapist or peer support group, wherever you are.
• Source verification — in jurisdictions without regulated supply, product identity cannot be verified. Wild foraged mushrooms carry mis-identification risks. Capsule products may contain adulterants. These risks are reduced but not eliminated in regulated frameworks.

How to Navigate These Guides

These regional guides are organised to help you efficiently find what you need depending on your situation:

• If you are in or travelling to Oregon — see the Oregon Guide for detailed information on licensed service centres, costs, and what to expect.
• If you are in Colorado — see the Colorado Guide for Proposition 122, personal possession rights, and healing centre access.
• If you are in the UK — see the UK Guide for legal status, research trials, harm reduction, and Netherlands truffle tourism context.
• If you are in Canada — see the Canada Guide for SAP access, BC decriminalisation, research institutions, and province-by-province context.
• For a broad continent overview — use the regional overview pages for the Americas, Europe, Oceania, Asia, and Africa.
• For legal comparisons across jurisdictions — see our Legal Status Guide.
• For safety guidance applicable anywhere — see our Safety & Harm Reduction section.

Browse All Regional Guides

Frequently Asked Questions

Do laws change often?

Yes — faster than almost any other area of drug law. At least a dozen significant legal changes affecting psilocybin have occurred globally since 2020. Always verify the current status through an authoritative local source (government health department, legal organisation, or specialist advocacy group in your jurisdiction) before making decisions based on this or any guide.

What is the difference between decriminalisation and legalisation?

Decriminalisation removes criminal penalties for personal possession but does not create a legal supply. If you are caught with a small amount in a decriminalised jurisdiction, you may face an administrative sanction (fine, mandatory referral to services) rather than criminal prosecution — but how you obtained the substance was still likely illegal. Legalisation or regulated access creates a licensed supply chain where the substance can be legally produced, sold, and consumed under defined conditions.

Can I travel between countries with psilocybin that is legal at my destination?

No. Crossing an international border with a controlled substance is governed by the law at the point of departure, the point of arrival, and international aviation law — not by the legality at your destination. Importing psilocybin into almost any country remains a serious criminal offence regardless of where you came from. Even travelling from Jamaica (where psilocybin is legal) to the US with psilocybin would be federal drug importation offence.

What if I have a difficult experience during a session?

The Fireside Project (+1-623-473-7433, also reachable by text) provides free, non-judgmental psychedelic peer support and is available internationally by phone. In any emergency where there is a physical safety concern, call local emergency services and be honest with medical staff about what was taken. Medical professionals prioritise patient welfare and their primary concern is your health, not legal enforcement.

Are psychedelic mushroom spores legal to possess?

In many jurisdictions, mushroom spores are in a legal grey area because they do not themselves contain psilocybin or psilocin. In the US, spores are sold for microscopy purposes in most states (exceptions include California, Georgia, and Idaho where they are explicitly illegal). In the UK, spores occupy a similar grey area but germinating them to produce mushrooms is illegal production of a Class A drug. In all cases, intent matters — purchasing spores for the purpose of growing psilocybin-producing mushrooms may be prosecuted even where simple spore possession is not explicitly prohibited.

How accurate are the species maps and regional fruiting data?

Seasonal and geographic data about psilocybin mushroom species distribution is indicative, not definitive. Microclimates, year-to-year weather variation, and rapidly changing populations mean field conditions can differ substantially from any published map. Always cross-check with recent local reports, reputable identification resources, and — for safety critical decisions — expert confirmation. Never ingest a mushroom you are not 100% certain of the identity.

What is the safest way to access psilocybin?

From a harm-reduction standpoint, the safest access involves: verified product identity (licensed and tested supply where available); professional facilitation; comprehensive health screening; preparation and integration support; and a setting designed for psychological safety. Oregon's licensed service centres and Colorado's healing centres provide this framework. Australia's psychiatric prescribing pathway provides it within a clinical context. Outside of regulated frameworks, harm reduction focuses on minimising the most significant risks: health contraindications, known product identity, set and setting, sober sitter, and integration planning.